Studies of the clinical significance of many biomarkers often require large numbers of specimens and many years of patient follow-up. An alternative to completely prospective study designs, which would require years of waiting for answers and would also be prohibitively expensive, is to obtain specimens for which long-term clinical follow-up and considerable correlative clinical data is already available. Nearly 20 years ago the San Antonio breast cancer program began banking such specimens and data for the use of its own investigators. Now, under the SPORE, we have used this experience to develop a Resource for the use of SPORE and other NCI-funded investigators everywhere. We are presently able to provide on a perpetual, self-renewing basis 11,600 specimens per year with important clinical and laboratory data (ER and PgR, S-phase and ploidy), and 1,300 per year with all of these data plus 5-year clinical follow-up. This Resource has already provided specimens for 25 projects, about half of which are outside San Antonio, and has promised support for 8 more. Investigators from all of the other breast cancer SPOREs are included in this support. Specific functions of the Resource include: 1. Receiving new breast cancer specimens and adding them to a computerized inventory system. 2. Maintaining the stored specimens in ultralow temperature freezers. 3. Determining whether the specimens are of sufficient quality for various assays. 4. Maintaining a computerized inventory of tissue in the Resource. 5. Obtaining continual clinical follow-up on a major subset (currently nearly 25,000) of the patients who provided the tumor specimens. 6. Maintaining quality control standards for all data collected. 7. Retrieving banked tissue and distributing the specimens to other NCI- funded investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058183-05
Application #
5209187
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Sukumaran, Sujita; Watanabe, Norihiro; Bajgain, Pradip et al. (2018) Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov 8:972-987
Kaochar, Salma; Mitsiades, Nicholas (2018) A Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab 29:366-368
Bhat, Raksha R; Yadav, Puja; Sahay, Debashish et al. (2018) GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer. Breast Cancer Res Treat 170:279-292
Hertz, D L; Kidwell, K M; Hilsenbeck, S G et al. (2017) CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. Breast Cancer Res Treat 166:277-287
Yu, L; Liang, Y; Cao, X et al. (2017) Identification of MYST3 as a novel epigenetic activator of ER? frequently amplified in breast cancer. Oncogene 36:2910-2918
Guven, Adem; Villares, Gabriel J; Hilsenbeck, Susan G et al. (2017) Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. Acta Biomater 58:466-478
Veeraraghavan, Jamunarani; De Angelis, Carmine; Reis-Filho, Jorge S et al. (2017) De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. Breast 34 Suppl 1:S19-S26
Xu, Xiaowei; De Angelis, Carmine; Burke, Kathleen A et al. (2017) HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res 23:5123-5134

Showing the most recent 10 out of 306 publications